Sinphar Pharmaceutical Co. Ltd. Statistics
Sinphar Pharmaceutical Co. Ltd. (1734) Stock Statistics & Valuation Metrics
Total Valuation
Sinphar Pharmaceutical Co. Ltd. has a market cap or net worth of TWD 6.03B. The enterprise value is TWD 6.94B.
- Market Cap
- TWD 6.03B
- Enterprise Value
- TWD 6.94B
Share Statistics
Sinphar Pharmaceutical Co. Ltd. has 201,608,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 201,608,580
- Owned by Insiders
- ―
- Owned by Institutions
- 2.01%
Financial Efficiency
Sinphar Pharmaceutical Co. Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 6.84%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 6.84%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 1.84M
- Profits Per Employee
- 199.97K
- Employee Count
- 1,829
- Asset Turnover
- 0.55
- Inventory Turnover
- 2.64
Valuation Ratios
The current PE Ratio of Sinphar Pharmaceutical Co. Ltd. is 16.21. Sinphar Pharmaceutical Co. Ltd.’s PEG ratio is 1.85.
- PE Ratio
- 16.21
- PS Ratio
- 1.76
- PB Ratio
- 1.64
- Price to FCF
- 18.63
- Price to Operating Cash Flow
- 9.46
- PEG Ratio
- 1.85
Income Statement
In the last 12 months, Sinphar Pharmaceutical Co. Ltd. had revenue of 3.37B and earned 365.75M in profits. Earnings per share was 1.92.
- Revenue
- 3.37B
- Gross Profit
- 1.46B
- Operating Income
- 416.86M
- Pretax Income
- 401.52M
- Net Income
- 365.75M
- EBITDA
- 689.70M
- Earnings Per Share (EPS)
- 1.92
Cash Flow
In the last 12 months, operating cash flow was 598.46M and capital expenditures -272.11M, giving a free cash flow of 326.35M billion.
- Operating Cash Flow
- 598.46M
- Free Cash Flow
- 326.35M
- Free Cash Flow per Share
- 1.74
Dividends & Yields
Sinphar Pharmaceutical Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 3.16%
- Dividend Per Share
- ―
- Dividend Yield
- 3.16%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.37%
- Earnings Yield
- 6.21%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -0.49%
- 50-Day Moving Average
- 31.31
- 200-Day Moving Average
- 29.55
- Relative Strength Index (RSI)
- 23.61
- Average Volume (3m)
- 204.56K
Important Dates
Sinphar Pharmaceutical Co. Ltd. upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Sinphar Pharmaceutical Co. Ltd. as a current ratio of 2.50, with Debt / Equity ratio of 43.84%
- Current Ratio
- 2.50
- Quick Ratio
- 1.78
- Debt to Market Cap
- 0.30
- Net Debt to EBITDA
- 0.94
- Interest Coverage Ratio
- 12.32
Taxes
In the past 12 months, Sinphar Pharmaceutical Co. Ltd. has paid 47.25M in taxes.
- Income Tax
- 47.25M
- Effective Tax Rate
- 0.12
Enterprise Valuation
Sinphar Pharmaceutical Co. Ltd. EV to EBITDA ratio is 9.67, with an EV/FCF ratio of 20.37.
- EV to Sales
- 1.93
- EV to EBITDA
- 9.67
- EV to Free Cash Flow
- 20.37
- EV to Operating Cash Flow
- 11.11
Balance Sheet
Sinphar Pharmaceutical Co. Ltd. has TWD 1.60B in cash and marketable securities with TWD 2.05B in debt, giving a net cash position of -TWD 450.75M billion.
- Cash & Marketable Securities
- TWD 1.60B
- Total Debt
- TWD 2.05B
- Net Cash
- -TWD 450.75M
- Net Cash Per Share
- -TWD 2.24
- Tangible Book Value Per Share
- TWD 19.52
Margins
Gross margin is 43.99%, with operating margin of 11.82%, and net profit margin of 10.19%.
- Gross Margin
- 43.99%
- Operating Margin
- 11.82%
- Pretax Margin
- 11.78%
- Net Profit Margin
- 10.19%
- EBITDA Margin
- 19.92%
- EBIT Margin
- 12.46%
Analyst Forecast
The average price target for Sinphar Pharmaceutical Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 2.44%
- EPS Growth Forecast
- -3.96%
